Quratis Inc. (KOSDAQ:348080)
3,575.00
+275.00 (8.33%)
At close: Nov 6, 2026
Quratis Revenue
Quratis had revenue of 320.27M KRW in the quarter ending June 30, 2026, a decrease of -33.30%. This brings the company's total for the last twelve months to 1.10B, down -41.14% year-over-year. In the year 2025, Quratis had annual revenue of 2.46B with 557.29% growth. That makes Quratis the 43,921st largest company in the world by revenue and 2,590th in South Korea.
Revenue (ttm)
1.10B
Revenue Growth
-41.14%
P/S Ratio
35.31
Revenue / Employee
n/a
Employees
n/a
Market Cap
41.93B
Revenue by Geography
- South Korea 828.51M 80.4%
- Asia 201.55M 19.6%
Fiscal year ended Dec 31, 2023 See the full Quratis breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.46B | 2.08B | 557.29% |
| Dec 31, 2024 | 373.80M | -656.26M | -63.71% |
| Dec 31, 2023 | 1.03B | -6.49B | -86.31% |
| Dec 31, 2022 | 7.52B | 5.94B | 373.65% |
| Dec 31, 2021 | 1.59B | 1.48B | 1,344.13% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| KoBioLabs | 75.41B |
| J2KBIO | 43.90B |
| ADBiotech | 12.57B |
| Eutilex.Co.,Ltd | 7.71B |
| QuadMedicine | 7.14B |
| HLB Pep | 5.54B |
| Parataxis Korea | 1.59B |
| Kainos Medicine | 1.40B |